Partially verified by Claude on 2026-05-07. Sources checked: Liu 2023 (PDF), Biagi 2010 (PDF), Hutchinson 2021 (PDF), Zheng 2020 (abstract via Crossref; PDF not downloadable), Bui 2019 DOI corrected. Biagi 2016 PDF not downloadable. PMID-only citations resolved to DOIs. Several corrections applied — see verified-scope in frontmatter and log.md.

Lactobacillus (genus, sensu stricto)

Lactobacillus is a gram-positive, rod-shaped, non-spore-forming bacterial genus that ferments sugars to lactic acid. In the context of the aging gut, the name “Lactobacillus” requires careful disambiguation: a landmark 2020 taxonomic reclassification by Zheng et al. split the historical genus into 25 genera, radically narrowing what “Lactobacillus” now refers to ¹. Most commercially important “probiotic Lactobacillus” strains are now assigned to sister genera (Lacticaseibacillus, Limosilactobacillus, Lactiplantibacillus, etc.). Abundance shifts in the aging gut are cohort-dependent and contested: some studies report modest increases in Lactobacillaceae in centenarians, while genus-level causal inference via Mendelian randomization suggests species-specific rather than genus-wide longevity associations ². The genus is the historical probiotic workhorse; RCT evidence in elderly populations shows modest, strain-specific benefits on immune markers and microbiota composition ³.

Taxonomy and the 2020 reclassification

Historical genus

Before 2020, “Lactobacillus” was one of the largest bacterial genera: >260 validly published species spanning enormously diverse ecological niches (gut, vagina, oral cavity, dairy ferments, plant surfaces, silage). The genus was held together largely by phenotype (gram-positive, rod, lactic acid fermenter) rather than phylogenetic coherence.

Zheng 2020 reclassification

Zheng et al. performed whole-genome sequence analysis of >250 Lactobacillus species and proposed splitting the genus into 25 distinct genera ¹. Key points:

The genus Lactobacillus sensu stricto now contains only the acidophilus group and related clades: L. acidophilus, L. delbrueckii (incl. subsp. bulgaricus), L. helveticus, L. crispatus, L. gallinarum, L. amylolyticus, L. amylovorus, L. gasseri, L. johnsonii, and close relatives.
Former “Lactobacillus” species in other clades were moved to new genera including:
- Lacticaseibacillus — e.g., L. rhamnosus → Lacticaseibacillus rhamnosus GG
- Limosilactobacillus — e.g., L. reuteri → Limosilactobacillus reuteri
- Lactiplantibacillus — e.g., L. plantarum → Lactiplantibacillus plantarum 299v
- Lentilactobacillus — e.g., L. buchneri
- Lacticaseibacillus — e.g., L. casei (Shirota / Yakult) → Lacticaseibacillus casei
The Lactobacillaceae family was simultaneously expanded to absorb Leuconostocaceae (Leuconostoc, Weissella, Oenococcus).

This wiki uses “Lactobacillus sensu stricto” to mean the restricted post-2020 genus (NCBI Taxonomy 1578). When citing older literature or commercial probiotics that use the historical name, context is required. See the “Probiotic strains” section below for current nomenclature.

Identity table

Field	Value
Genus	Lactobacillus Beijerinck 1901 (emended Zheng et al. 2020)
NCBI Taxonomy ID	1578
Phylum	Firmicutes
Class	Bacilli
Order	Lactobacillales
Family	Lactobacillaceae
Gram stain	Positive
Morphology	Rod-shaped, non-motile, non-spore-forming
Oxygen tolerance	Facultative anaerobic to microaerophilic (species-dependent)
Fermentation type	Homofermentative (L. delbrueckii, L. acidophilus) or heterofermentative (L. helveticus partial)
Primary metabolic product	L- or D-lactic acid (species-dependent stereochemistry)
Genome size range	~1.8–3.3 Mb

Biology and ecology

Fermentation

Lactobacillus spp. are lactic acid fermenters. Homofermentative species (most of the sensu stricto genus) convert glucose almost exclusively to lactic acid via glycolysis. Heterofermentative species additionally produce CO₂, ethanol, and acetate via the phosphoketolase pathway. The net result is environmental acidification, which creates a low-pH niche that excludes many enteric pathogens (colonization resistance / competitive exclusion).

Niches in the human body

Lactobacillus sensu stricto species are most abundant in:

Vaginal microbiome — L. crispatus, L. gasseri, L. jensenii are dominant in healthy, Lactobacillus-dominated vaginal communities (Ravel et al. 2011 framework). Vaginal Lactobacillus dominance is strongly protective against BV, STIs, and preterm birth — an aging-relevant niche primarily for premenopausal context; estrogen decline at menopause reduces vaginal Lactobacillus colonization.
Upper GI / small intestine — L. acidophilus, L. helveticus colonize jejunal/ileal mucosa.
Colonic gut — Lactobacillus sensu stricto typically represents <1% of fecal microbiota in healthy adults; dominant gut colonizers are anaerobes (Firmicutes Clostridiales, Bacteroidetes). The gut fraction is minor compared to the vaginal or oral niches.
Dairy ferments — L. delbrueckii subsp. bulgaricus (yogurt), L. helveticus (Swiss-type cheese) are technological organisms with limited gut persistence.

Lactate cross-feeding loop

A key ecological role: Lactobacillus-derived lactic acid is cross-fed to secondary fermenters (especially Anaerostipes rhamnosivorans and related Lachnospiraceae) that convert lactate to butyrate ⁴. This metabolic handoff is one mechanism by which Lactobacillus colonization can indirectly boost butyrate production even though Lactobacillus itself does not produce butyrate. Butyrate is the primary energy substrate for colonocytes and a key anti-inflammatory metabolite in the gut (see scfa-signaling). This cross-feeding mechanism parallels the Bifidobacterium-acetate → butyrate-producer cross-feeding loop described for bifidobacterium.

Dimension	Status
Pathway conserved in humans?	partial — in vitro co-culture evidence; human in vivo quantification limited
Phenotype conserved in humans?	partial — SCFA shifts observed with probiotic interventions; attribution to lactate cross-feeding specifically unclear
Replicated in humans?	no — mechanistic chain not directly validated in controlled human trials needs-human-replication

Aging-associated abundance shifts

Gut abundance: contested directionality

Unlike bifidobacterium, whose age-associated gut decline is highly consistent across cohorts, Lactobacillus abundance changes with aging are cohort-dependent and directionally contested:

Biagi 2010 (PLoS ONE; n=84, Italian multi-age cohort: 21 centenarians, 22 elderly 63–76 yr, 20 young adults 25–40 yr, plus 21 centenarian offspring) found significantly altered gut microbiota composition in centenarians versus younger adults (MCPP P=0.002). The centenarian microbiota was enriched in Bacilli class (driven by Staphylococcus and Clostridium leptum group) and Proteobacteria (including pathobionts such as Klebsiella pneumoniae, Vibrio, Pseudomonas, Serratia), with a dramatic increase in Eubacterium limosum et rel. (~15-fold vs elderly and young) and a significant decrease in Faecalibacterium prausnitzii (butyrate-producer). The paper does not report Lactobacillus or Lactobacillus-related taxa as enriched in centenarians — the Bacilli-class enrichment is primarily Staphylococcus and related organisms. Bifidobacterium was significantly lower in centenarians vs young adults (P=0.023). ⁵. needs-replication
Biagi 2016 (Current Biology; Italian adults through semi-supercentenarians 105–109 yr) — characterized the core microbiota across ages. The study found enrichment of Akkermansia, Bifidobacterium, and Christensenellaceae in extreme longevity groups but did not identify Lactobacillus sensu stricto as a consistent longevity-enriched clade ⁶. needs-replication — claim derived from abstract; full-PDF verification pending.
Ji 2025 (GeroScience; Chinese long-lived populations including centenarians from Northeastern China, n=142) — found enrichment of Lactobacillus salivarius (now reclassified to Ligilactobacillus salivarius) in long-lived individuals. Species-specific finding; genus-level generalization unreliable ⁷. needs-replication — single cohort, observational, single-region.

Net assessment: contradictory-evidence — Directional abundance claims for Lactobacillus in aging are unreliable at the genus level. Species-specific effects (e.g., L. amylovorus or Ligilactobacillus salivarius in centenarians) may be real, but genus-wide enrichment or depletion is not established. Confounders (diet, geography, antibiotic history, comorbidities, 16S vs shotgun methodology, taxonomic resolution) obscure cross-cohort comparisons.

Mendelian randomization — causal signal

Liu et al. 2023 applied bidirectional two-sample Mendelian randomization (GCTA-GSMR as primary method; IVW, MR-Egger, weighted median, MR-PRESSO as sensitivity analyses) to the gut and oral microbiome and human longevity. Gut microbiome GWAS: N=1539 individuals (4D-SZ cohort, 500 gut microbial features). Longevity GWAS (outcome, discovery): N=4477 (2178 centenarians + 2299 middle-aged controls, CLHLS cohort). Longevity replication dataset: N=6548. Mean F-statistic for gut microbiome instruments: 51.4 (indicating strong instruments). Key finding relevant to Lactobacillus: in the forward MR (microbiome → longevity), genetically predicted Lactobacillus amylovorus (probiotic species, Lactobacillus sensu stricto) abundance was positively associated with longevity (β=0.09, p=0.014). However, the genus-level Lactobacillus was negatively associated with longevity (Figure 1a; genus listed among features negatively correlated with longevity in Chinese cohort, alongside Streptococcus, Coprococcus, and Fusobacterium nucleatum). Species-level and genus-level effects diverge substantially — genus-level generalization should not be made from the L. amylovorus finding. Cross-population replication in European cohorts (MiBioGen, Dutch, Finnish) showed few overlapping causalities; MR results for Lactobacillus-related taxa were not consistently replicated across ethnicities. ² needs-replication (single MR study; no European replication of the L. amylovorus signal)

Probiotic strains and current nomenclature

Many of the best-characterized “Lactobacillus” probiotic strains used in clinical trials are no longer in the genus Lactobacillus sensu stricto following the 2020 reclassification. The table below maps historical names (used in most trial literature) to current taxonomy:

Historical name	Current name	Genus	Key probiotic use
L. rhamnosus GG	Lacticaseibacillus rhamnosus GG	Lacticaseibacillus	GI tract; children / elderly
L. reuteri DSM 17938	Limosilactobacillus reuteri DSM 17938	Limosilactobacillus	Gut; bone density (older adults)
L. plantarum 299v	Lactiplantibacillus plantarum 299v	Lactiplantibacillus	GI; IBS
L. casei Shirota (Yakult)	Lacticaseibacillus casei Shirota	Lacticaseibacillus	Immune; elderly trials
L. acidophilus NCFM	L. acidophilus NCFM	Lactobacillus (retained)	Gut colonization; dairy
L. delbrueckii subsp. bulgaricus	L. delbrueckii subsp. bulgaricus	Lactobacillus (retained)	Yogurt ferment; limited GI persistence
L. helveticus R0052	L. helveticus R0052	Lactobacillus (retained)	Cheese; anxiety/sleep RCTs
L. crispatus CTV-05	L. crispatus CTV-05	Lactobacillus (retained)	Vaginal colonization; BV prevention

For the remainder of this page, “Lactobacillus” includes all organisms from the historical genus for the purpose of summarizing trial evidence, with current nomenclature in parentheses where relevant.

Probiotic interventions in elderly populations

Systematic review evidence

Hutchinson et al. 2021 systematically reviewed 17 RCTs of probiotic supplementation in healthy older adults (≥60 yr) ³. Key findings:

Gut microbiota composition was altered in nearly all trials — most consistent outcome. Supplemented strains showed transient colonization; microbiota returned toward baseline after cessation.
Humoral immunity (serum IgA, NK cell activity, influenza vaccine seroconversion) showed modest improvements in some trials; results were heterogeneous and the review did not pool effect sizes due to methodological variability.
Infection incidence/duration (upper respiratory, gastrointestinal) — mixed findings. Some trials reported reductions in cold duration; others null.
Cognitive function, lipid profiles, digestion — limited evidence, mostly single-trial.
Strains commonly examined: L. acidophilus NCFM, L. delbrueckii subsp. bulgaricus OLL1073R-1, Lacticaseibacillus rhamnosus GG, Lacticaseibacillus casei DN-114 001.

The review concluded that probiotic supplementation is safe in healthy elderly but has limited, strain-specific benefits across non-GI outcomes.

Dimension	Status
Pathway conserved in humans?	yes — immune-modulation via gut-associated lymphoid tissue
Phenotype conserved in humans?	partial — microbiota composition effects consistent; immune/infection effects strain-dependent and modest
Replicated in humans?	partial — individual outcomes replicated in some strains but not across-the-board

Strain-specific aging-trial highlights

Lacticaseibacillus casei Shirota (Yakult): Most studied in elderly Japanese cohorts. Multiple small RCTs reported improved NK cell activity, reduced incidence of upper respiratory infections, and constipation relief. Data predominantly from single-group, industry-sponsored trials; effect sizes modest. needs-replication — independent non-industry replication limited.

Lacticaseibacillus rhamnosus GG: Chaiyasut et al. 2024 (n=small; 8-week intervention) in healthy elderly: significant improvement in LDL cholesterol, altered microbiome composition ⁸. Single small study. needs-replication

Limosilactobacillus reuteri DSM 17938: Skeletal data in postmenopausal women showed improved bone mineral density in a double-blind RCT (Jansson 2019, not independently verified here). Gut-bone axis proposed mechanism. unsourced — verify primary source before relying on this claim.

Lactobacillus helveticus R0052 (combined with Bifidobacterium longum): Anxiety/depression outcomes in stressed adults; gut-brain axis mechanism. Aging-specific geriatric data not established.

FMT with Lactobacillus-enriched donor microbiomes

Zhou et al. 2024 used human fecal transplants containing centenarian-derived Bifidobacterium bifidum LTBB21J1 and Lacticaseibacillus casei LTL1361 in D-galactose-induced aging mice ⁹. Mixed probiotic groups showed reduced neuronal damage, increased antioxidant capacity, and decreased inflammation. Preclinical only; D-galactose model is not a canonical aging model. See fmt for the broader FMT-aging context. needs-human-replication

Mechanisms relevant to aging biology

Pathogen exclusion and immunomodulation

Acidification of the gut lumen by Lactobacillus lactic acid production and secretion of bacteriocins (antimicrobial peptides) suppresses enteric pathogens and potentially modulates the dysbiotic shifts associated with aging. In aging, reduced gastric acid secretion and slower gut motility create a more permissive environment for facultative pathogens — Lactobacillus colonization may partially counteract this. Evidence is indirect and extrapolated from non-aging contexts. no-mechanism — quantitative contribution to aging-specific pathogen exclusion not established.

Regulatory T-cell induction

Some Lactobacillus strains (notably L. reuteri) induce regulatory T-cells (Tregs) in the intestinal mucosa, potentially countering the age-associated shift toward pro-inflammatory Th1/Th17 skewing. This mechanism links to the chronic-inflammation hallmark. Data are primarily from mouse models; species/strain specificity is high. needs-human-replication

SCFA cross-feeding

As noted in the biology section, lactate cross-feeding to butyrate producers is an indirect mechanism by which Lactobacillus colonization can support colonocyte health and mucosal barrier integrity. See scfa-signaling and gut-barrier for the downstream biology.

Gut-brain axis

Some Lactobacillus strains produce GABA and other neuroactive compounds; gut-brain axis effects are proposed for cognitive aging. Mechanistic evidence is preclinical; human aging-specific RCT data are limited. no-mechanism — the causal chain from Lactobacillus → GABA production → brain function in elderly is not established.

Limitations and gaps

contradictory-evidence — Genus-level aging abundance directionality is contested; species- and cohort-dependent. Do not generalize “Lactobacillus increases/decreases with aging” without specifying species, cohort, and methodology.
needs-replication — Most aging-specific Lactobacillus RCTs are small (n<50), single-center, and industry-affiliated; independent large-scale replication is lacking.
long-term-unknown — No Lactobacillus-focused lifespan extension study in mice published as of 2026-05-07; all preclinical work uses surrogate aging models (D-galactose, HFD) rather than natural aging.
needs-human-replication — Cross-feeding, Treg induction, and gut-brain axis mechanisms established in rodent models; human mechanistic quantification absent.
dose-response-unclear — Optimal dose, duration, and colonization persistence for aging-relevant outcomes have not been established in humans; probiotic doses range from 10⁸ to 10¹¹ CFU/day across trials with no systematic dose-ranging study in elderly.
Nomenclature hazard — Older literature, meta-analyses, and probiotic labeling continue to use the historical genus name. Readers and researchers must map historical “Lactobacillus” species to their current genus to correctly aggregate evidence. This wiki follows post-2020 nomenclature; strain-level specificity overrides genus-level claims ¹.

Footnotes

zheng-2020-lactobacillus-reclassification · doi:10.1099/ijsem.0.004107 · taxonomic / whole-genome phylogenetics · model: 261 Lactobacillus species (at March 2020); whole-genome phylogeny + pairwise average amino acid identity + clade-specific signature genes · Zheng J, Wittouck S, Salvetti E, Franz CMAP, Harris HMB et al. · Int J Syst Evol Microbiol 2020 · PDF: not downloadable (HTTP 403 from publisher; archive status: failed; OA URL at microbiologyresearch.org inaccessible); key claims verified against Crossref abstract · abstract confirms: 25 genera total (23 novel + emended Lactobacillus + Paralactobacillus); Lacticaseibacillus, Lactiplantibacillus, Limosilactobacillus, Lentilactobacillus all confirmed as novel genera in abstract genus list · citation percentile: 100% (2933 citations as of 2026-05-07) · no-fulltext-access (abstract-only verification) ↩ ↩² ↩³
liu-2023-mr-microbiome-longevity · doi:10.1038/s41598-023-31115-8 · Mendelian randomization (bidirectional two-sample MR; primary method GCTA-GSMR; IVW, MR-Egger, weighted median, MR-PRESSO as sensitivity analyses) · exposure GWAS: N=1539 (gut microbiome, 4D-SZ cohort); outcome GWAS: N=4477 (longevity discovery, CLHLS: 2178 centenarians + 2299 controls); replication longevity N=6548 · mean gut microbiome instrument F-statistic: 51.4 · model: human GWAS summary statistics (Chinese cohort primary; European MiBioGen/Dutch/Finnish for cross-population validation) · Liu X, Zou L, Nie C et al. · Scientific Reports 2023 · PDF: verified against downloaded PDF · L. amylovorus: β=0.09, p=0.014 (positively associated with longevity); genus-level Lactobacillus negatively associated with longevity in forward MR · needs-replication (single MR study; L. amylovorus signal not replicated in European cohorts) ↩ ↩²
hutchinson-2021-probiotics-elderly-review · doi:10.3390/microorganisms9061344 · systematic review · n=17 RCTs · individual trial sample sizes ranged from 18 to 1,072 participants (paper does not report a pooled N; no meta-analysis performed due to heterogeneity) · model: healthy older adults ≥60 yr; multiple Lactobacillus/probiotic strains · Hutchinson AN, Bergh C, Kruger K et al. · Microorganisms 2021 · PDF: verified against downloaded PDF ↩ ↩²
bui-2019-anaerostipes-lactate-crossfeeding · doi:10.3389/fmicb.2019.02449 [CORRECTED — original seeder had wrong DOI: 10.3389/fmicb.2019.02653 resolves to an unrelated mycotoxin paper by Camardo Leggieri et al.; correct DOI confirmed via Crossref] · in-vitro co-culture · model: Anaerostipes rhamnosivorans + lactic acid bacteria co-culture · Bui TPN, Schols HA, Jonathan M et al. · Frontiers in Microbiology 2019 · demonstrates lactate cross-feeding to butyrate production in vitro; human in vivo quantification not available · needs-human-replication · Note: underlying PDF not verified end-to-end against this corrected DOI ↩
biagi-2010-centenarian-microbiota · doi:10.1371/journal.pone.0010667 · observational (HITChip 16S rRNA microarray + qPCR) · n=84 total: 21 centenarians (avg 100.5 yr), 22 elderly (avg 72.7 yr), 20 young adults (avg 31 yr), 21 centenarian offspring (avg 67.5 yr) · Emilia Romagna, Italy · Biagi E, Nylund L, Candela M et al. · PLoS ONE 2010 · PDF: verified against downloaded PDF · key centenarian findings: Eubacterium limosum ~15-fold increase vs elderly; F. prausnitzii significantly decreased; Proteobacteria enrichment (pathobionts); Bifidobacterium lower vs young (P=0.023); Bacilli class higher but driven by Staphylococcus and C. leptum group, NOT Lactobacillus per se · needs-replication ↩
biagi-2016-extreme-longevity-microbiota · doi:10.1016/j.cub.2016.04.016 · observational (shotgun + 16S) · model: Italian adults through semi-supercentenarians (105–109 yr) · Biagi E, Franceschi C, Rampelli S et al. · Current Biology 2016 · PDF: pending (green OA) — Lactobacillus abundance claim on this page unverified against full PDF; abstract confirms Akkermansia/Bifidobacterium enrichment, not Lactobacillus sensu stricto · needs-replication ↩
ji-2025-longlived-china-microbiome · pmid:39505797 · doi:10.1007/s11357-024-01419-2 · pmc:PMC11978580 · observational · n=142 individuals aged 55–102 yr (Northeastern China long-lived cohorts) · model: oral and gastrointestinal microbiome across age groups · Ji Y, Sun H, Wang Y et al. · GeroScience 2025 · Ligilactobacillus salivarius (formerly L. salivarius) enriched in long-lived group · needs-replication (single cohort, single region) · Note: underlying PDF not verified end-to-end ↩
chaiyasut-2024-lrhamnosus-elderly · pmid:38731665 · doi:10.3390/foods13091293 · pmc:PMC11083618 · rct (small n) · model: healthy elderly adults; 8-week Lacticaseibacillus rhamnosus supplementation · Chaiyasut C, Sivamaruthi BS, Thangaleela S et al. · Foods 2024 · significant LDL improvement reported; small sample, short duration · needs-replication · Note: underlying PDF not verified end-to-end ↩
zhou-2024-fmt-centenarian-aging-mice · pmid:38647087 · doi:10.1021/acs.jafc.3c09815 · in-vivo · model: D-galactose-induced aging mice; centenarian-derived Bifidobacterium bifidum LTBB21J1 + Lacticaseibacillus casei LTL1361 FMT · Zhou F, Zhang Q, Zheng X et al. · J Agric Food Chem 2024 · D-galactose aging model only; not a natural aging study · needs-human-replication · Note: underlying PDF not verified end-to-end ↩

🧬 Aging Wiki

Explorer

lactobacillus